Investigating how high doses of thiamine may help in Alzheimer's disease by reducing harmful compounds.
Mechanistic links between the benefits of pharmacologically high thiamine (vitamin B1) in Alzheimer's disease to Advanced Glycation Endproducts (AGE)
This study is looking at whether a special form of vitamin B1 called benfotiamine can help improve symptoms for people with Alzheimer's disease, especially those who have a certain genetic risk factor, by reducing harmful compounds in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Winifred Masterson Burke Med Res Inst NIH-funded |
| Lab location | 1 site (White Plains, United States) |
| Project ID | NIH-11019797 on NIH RePORTER |
What this research studies
This research explores the potential benefits of pharmacological thiamine, specifically through the drug benfotiamine, in patients with Alzheimer's disease. It aims to understand how thiamine can reduce the formation of advanced glycation endproducts (AGE), which are harmful compounds linked to the progression of Alzheimer's. The study will involve clinical trials to assess the effects of high thiamine levels on symptoms and biomarkers in patients, particularly focusing on those with the APOE4 genetic risk factor. By examining these mechanisms, the research seeks to optimize thiamine's therapeutic effects for better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those who may have a deficiency in thiamine or carry the APOE4 genotype.
Not a fit: Patients with Alzheimer's disease who do not have thiamine deficiency or those with advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for Alzheimer's disease, potentially slowing its progression and alleviating symptoms.
How similar studies have performed: Previous studies have shown promising results with thiamine supplementation in Alzheimer's models, suggesting potential for success in this novel approach.
Where this research is happening
White Plains, United States
- Winifred Masterson Burke Med Res Inst — White Plains, United States (Active)
Researchers
- Principal investigator: Gibson, Gary E — Winifred Masterson Burke Med Res Inst
- Study coordinator: Gibson, Gary E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.